Golimumab: A Review in Inflammatory Arthritis.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 263, doi. 10.1007/s40259-017-0217-6
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2017 AND VI 31 AND IP 3
Results: 11
1
2
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 175, doi. 10.1007/s40259-017-0218-5
- By:
- Publication type:
- Article
3
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 223, doi. 10.1007/s40259-017-0219-4
- By:
- Publication type:
- Article
4
PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 167, doi. 10.1007/s40259-017-0220-y
- By:
- Publication type:
- Article
5
Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 239, doi. 10.1007/s40259-017-0221-x
- By:
- Publication type:
- Article
6
Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 251, doi. 10.1007/s40259-017-0222-9
- By:
- Publication type:
- Article
7
Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 151, doi. 10.1007/s40259-017-0223-8
- By:
- Publication type:
- Article
8
Interleukin-1 Blockade: An Update on Emerging Indications.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 207, doi. 10.1007/s40259-017-0224-7
- By:
- Publication type:
- Article
9
Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 143, doi. 10.1007/s40259-017-0225-6
- By:
- Publication type:
- Article
10
CT-P10 (Truxima™): A Rituximab Biosimilar.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 275, doi. 10.1007/s40259-017-0226-5
- By:
- Publication type:
- Article
11
Biosimilars in the United States: Emerging Issues in Litigation.
- Published in:
- BioDrugs, 2017, v. 31, n. 3, p. 189, doi. 10.1007/s40259-017-0216-7
- By:
- Publication type:
- Article